Abstract: A method of diagnosing suppression in a subject is disclosed. The method involves prompting the subject to engage in three neurological assessments and recording the results from each test. The neurological assessments are a Brock String test, a Bates Field Splitters test, and a Thumb Thing test. The results of these tests are used to calculate a singular score that indicates the presence of suppression in the subject. In one embodiment, the method further includes using the results of the tests to diagnose the subject with near suppression, far suppression, or both.

Abstract: A method of determining that an absence of suspicion of neurological injury is indicated in a subject is disclosed. The method involves prompting the subject to engage in three or more of the following neurological assessments: a) Reading Saccades, b) Near/far accommodation using Hart charts of different font sizes; c) Brock string, d) Maddox rod, e) closed-eye turns, f) Near Point of Convergence, and g) PERRLA with consensual reflex. The data from the neurological assessments is used to determine that an absence of suspicion of neurological injury is indicated in the subject.

Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolizm using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.

Abstract: Described herein are devices and methods for training a subject to maintain their head in a proper position during an activity by training the individual to concentrate on a focal point and to maintain a constant line of sight during an activity. An aspect of the invention is directed to devices and methods utilizing retinal retention to train the subject to focus on a focal point during an activity. Another aspect of the invention is directed to devices and methods utilizing visual memory acquisition to train the subject.

Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.

Abstract: Amplification primers, sequencing primers, kits for screening, and screening methods for identifying a SLC6A8 creatine transporter gene mutation are disclosed. The screening method includes treating a sample of DNA with polymerase chain reaction amplification primers for amplifying regions of the DNA having SLC6A8 to produce a first, second, and third amplification product, sequencing the first, second, and third amplification products with sequencing primer pairs to provide a DNA sequence of SLC6A8 in the sample, and comparing the DNA sequence of SLC6A8 with a reference DNA sequence of SLC6A8.

Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism using cyclocreatine or a pharmaceutically acceptable salt thereof are discussed.

Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.

Abstract: The present invention provides methods for assessing a condition in an individual by analyzing a cerebrospinal fluid sample from the individual, for example, by spectroscopy. Further, the invention provides methods for determining an amount of blood in the cerebrospinal fluid sample; methods for determining concentrations of analytes in the cerebrospinal fluid sample; methods for determining a length of time the blood has been in the cerebrospinal fluid sample; and methods for rapidly obtaining a differential diagnosis between conditions indicated by blood in the cerebral spinal fluid. Moreover, the present invention provides instruments capable of rapidly assessing a condition in and individual by point-of-care analysis of a cerebral fluid sample from an individual.

Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.

Abstract: Methods for enhancing the lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.

Abstract: Methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of lysis-inhibiting amounts of apolipoprotein E4, and methods for inhibiting lysis of coagulated blood and reducing risk of excessive lysis comprising administration of a specific level of a lysis-inhibiting agent wherein the specific level is based on the apolipoprotein phenotype of an individual, are provided. Methods for enhancing lysis of coagulated blood by administration of an Apo E peptide fragment to blood containing a clot lysis agent are also provided.

Abstract: Methods for treating cognitive dysfunction by modulating brain energy metabolism are discussed.

Abstract: Methods for inhibiting the lysis of coagulated blood comprise administering to blood a lysis-inhibiting amount of apolipoprotein E4 (Apo E4) or a therapeutic derivative thereof. Methods for reducing the risk of excessive blood clot lysis comprise administering the blood a lysis-inhibiting amount of Apo E4 or a therapeutic derivative thereof. Additional methods for inhibiting the lysis of coagulated blood comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4 wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the risk of excessive blood clot lysis comprise administering to an individual's blood a specific level of a lysis-inhibiting amount of Apo E4, wherein the specific level is based upon the apolipoprotein phenotype of the individual. Additional methods for enhancing the lysis of coagulated blood comprise administering to blood containing a clot lysis agent an Apo E peptide fragment.

Abstract: Methods for enhancing teh lysis of coagulated blood comprise administering to coagulated blood a combination of clot clysis agent and a lysis enhancing amount of apolipoprotein E2 (Apo E2) or a therapeutic derivative thereof. Methods for reducing the risk of blood coagulation comprise administering to blood a combination of a clot lysis agent and a lysis enhancing amount of Apo E2 or a therapeutic derivative thereof. Additional methods for enhancing the lysis of coagulated blood comprise administering to an individual a specific level of clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual. Further methods for reducing the riks of blood coagulation comprise administering to blood a specific level of a clot lysis agent wherein the specific level is based upon the apolipoprotein phenotype of the individual.

Abstract: The application concerns oxidative metabolism in smooth muscle cells and to methods and materials related thereto. Provided is a method which is a medium suitable for the support of oxidative metabolism comprises: 1) incubating a cell or tissue sample with a specimen derived from a patient wherein the sample comprises smooth muscle cells; 2) measuring a marker of oxidative metabolism of the cell or tissue sample; and 3) detecting an increase in oxidative metabolism which is not attributable to a contractile demand for ATP, such as an increase in oxidative metabolism being indicative of the existence in a patient of an agent or combination of agents able to cause an increase in oxidative metabolism in smooth muscle cells.

Abstract: Disclosed are methods for measuring non-contractile oxidative metabolism in smooth muscle cells comprising providing a medium suitable for the support of oxidative metabolism, incubating a cell or tissue sample with a specimen from a patient, measuring a marker of oxidative metabolism in the incubate, and detecting an increase in oxidative metabolism which is not attributable to a contractile demand for ATP. Such an increase in oxidative metabolism will be indicative of the existence of an agent or combination of agents able to cause an increase in oxidative metabolism in smooth muscle cells, and thus provides means for diagnosing and monitoring various pathologies associated therewith.